Drug Profile
Research programme: ras protein inhibitors - Concordia Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Concordia Pharmaceuticals
- Class
- Mechanism of Action Ras protein inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glioma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glioma in USA (PO)
- 31 Aug 2007 Preclinical trials in Glioma in USA (PO)